Angiosarcoma: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 414: Line 414:
*T1/T2: heterogeneous areas of hyperintensity suggestive of a mixed tumour and [[hemorrhage]]
*T1/T2: heterogeneous areas of hyperintensity suggestive of a mixed tumour and [[hemorrhage]]
*T1 C+ (Gd): heterogeneous enhancement
*T1 C+ (Gd): heterogeneous enhancement
====Biopsy====


== Treatment ==
== Treatment ==

Revision as of 04:12, 15 February 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Mohsen Basiri M.D.

Synonyms and keywords: Hemangiosarcoma; Pulmonary angiosarcoma; Vascular sarcoma

Overview

Angiosarcoma is a rare malignant vascular neoplasm of endothelial-type cells that line vessel walls. The peak age of incidence appears to be the 7th decade, and men are affected more than women. Angiosarcoma was first described by Dr. Juan Rosai, in 1976. The pathogenesis of angiosarcoma is characterized by a rapid and extensively infiltrating overgrowth of vascular epithelial cells. Angiosarcoma may arise in any part of the body, but is more common in soft tissue than in bone. Common angiosarcoma locations include the head and neck area, kidney, liver, lung, and and the most common site of radiation-induced angiosarcoma development is the breast. The PTPRB/PLCG1 genes are associated with the development of angiosarcoma; mutation of these genes result in aberrant angiogenesis. The imaging modality of choice for diagnosing angiosarcoma will depend on the location. For pulmonary angiosarcoma, the imaging modality of choice is enhanced CT scan. For other types angiosarcoma, the imaging modality of choice is MRI. On CT scan, findings suggestive of angiosarcoma may include vascular invasion, nodular enhancement (common), and a hypoattenuating mass. The mainstay adjuvant therapy for angiosarcoma is a doxorubicin-based regimen. The response rate for chemotherapy in patients with angiosarcoma is poor.

Historical Perspective

Angiosarcoma was first discovered by Dr. Juan Rosai, M.D. and colleagues in 1976.[1]

Classification

Angiosarcoma may be classified according to the clinical heterogeneity into two main groups, and every group can be subdivided into subtypes according to the anatomical location and etiology:[2] [3][4]

Angiosarcoma
Primary Secondary
Cutaneous Post Radiation Angiosarcoma
Breast Lymphedema-associated Angiosarcoma
Soft tissue and Bone Angiosarcoma due to exposure to mutatgens
Visceral

Staging

According to the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) and by Enneking classification, soft tissue sarcomas are classified to different stages based on the primary tumor characteristics, histological grading and the local or distant tumor involvement. Table below provides summarized information regarding staging of angiosarcoma:[5][6]

Stage Grade Site Metastasis
Ia Low grade (G1) Intracompartmental (T1) No metastasis (M0)
Ib Low grade (G1) Extracompartmental (T2) No metastasis (M0)
IIa High grade (G2) Intracompartmental (T1) No metastasis (M0)
IIb High grade (G2) Extracompartmental (T2) No metastasis (M0)
IIIa Low or High grade (G1-G2) Intracompartmental (T1) Metastasis (M1)
IIIb Low or High grade (G1-G2) Extracompartmental (T2) Metastasis (M1)

Pathophysiology

Pathogenesis

The pathogenesis of angiosarcoma is characterized by a rapid and extensive infiltrating overgrowth of vascular epithelial cells.[7] Angiosarcoma is a locally aggressive tumor with a high rate of lymph node infiltration and metastases.

Genetics

  • Angiosarcomas demonstrate obvious unregulated vascular-specific receptor tyrosine kinases containing TIE1, KDR, TEK and FLT.The up-regulation of these genes and over-expression of vascular endothelial growth factor receptors can cause endothelial cell expansion, angiogenesis, and also vascular leaks in the structure of vessels. [8][9][10][11]
    • KDR mutations are seen in primary breast angiosarcoma regardless of exposure to radiation.
    • High level MYC amplification is seen is seen in radiation- induced and lymphedema-associated angiosarcoma.
    • FLT4 amplification has been detected in 25% of secondary angiosarcomas.

Gross Pathology

On gross pathology, characteristic findings of angiosarcoma may include:[7]

  • Red/dark tan lesion
  • Typically poorly circumscribed

Microscopic Pathology

On microscopic histopathological analysis, characteristic findings of angiosarcoma may include:

Causes

The most common cause of angiosarcoma appears to be therapeutic radiation, which was a well-recognized cause of hepatic angiosarcoma in the era when the thorium containing contrast agent Thorotrast was employed. Presently, the breast is the most common anatomic site affected by radiation-induced angiosarcoma. Angiosarcomas may arise after exposure to vinyl chloride, although they remain rare tumors even in an exposed population. Angiosarcomas are also observed after lymphedema from any cause, be it surgical, filarial, or congenital, and defined as Stewart-Treves syndrome. Common causes of angiosarcoma include:[7]

Differentiating Angiosarcoma from Other Diseases

Angiosarcoma must be differentiated from other diseases that cause a highly vascular mass or non-healing cutaneous ulcerations such as:

Differentials for Cutaneous Angiosarcoma

Cutaneous angiosarcoma must be differentiated from other diseases with non-healing cutaneous ulcerations such as:[12][13][14]

Differentials for Non-cutaneous Angiosarcoma

Angiosarcoma must be differentiated from other diseases that cause a highly vascular mass such as:[15]

Epidemiology and Demographics

Incidence

  • In general 2% of soft tissue sarcomas are angiosarcomas, and the incidence of soft tissue sarcoma is about 6 per 100,000 person; on the other words,the incidence of angiosarcomas can be calculated approximately 1.2 per 1,000.000 person.[16][17]

Age

  • Angiosarcoma is more commonly observed among patients aged between 40 to 75 years old.The peak age of incidence appears is the 7th decade,[18]

Gender

  • Males are more commonly affected with angiosarcoma than females.[18]
  • The male to female ratio is 2:1.[18]

Race

  • There is no racial predilection for angiosarcoma. however, African-Americans in the U.S are rarely affected.[19]

Risk Factors

Common risk factors in the development of angiosarcoma include:[7]

Natural History, Complications and Prognosis

Natural History

  • The majority of patients with angiosarcoma remain asymptomatic for years.[7]
  • Early clinical features may include nonspecific symptoms, such as pain, fatigue, malaise, and nausea.
  • If left untreated, the majority of patients with angiosarcoma may rapidly progress to develop metastases.[18]

Complications

Common complications of angiosarcoma include:[7]

Prognosis

  • Prognosis is generally poor; the 5-­year survival rate of patients with angiosarcoma is approximately 12-33%.
  • Poor prognostic factors include patient age (> 65 years), retroperitoneal location, and large tumor size.[18]

Diagnosis

Diagnostic Study of Choice

  • There is no single diagnostic study of choice for the diagnosis of angiosarcomas, The imaging modality of choice for angiosarcoma or use of punch biopsy of skin will depend on the anatomic location of lesions.

Symptoms

  • Angiosarcomas occur at different anatomic sites and grow insidiously, then they can present with various misleading symptoms.[20] The most common clinical manifestation is a gradually enlarging, painless mass. [21]Some patients complain of pain or symptoms due to compression of adjacent neurovascular structures that causes pain or edema in an extremity.
  • Primary cutaneous, head and neck and breast angiosarcoma may present with skin thickening, erythema, or skin discoloration.[22][23]
  • Secondary angiosarcomas include radiation-Induced and lymphedema-associated Angiosarcoma have a distinct feature, presenting as single or several ecchymotic maculopapular cutaneous lesions in the radiation field or in areas exposed to chronic lymphedema.[24]

Physical Examination

Patients with angiosarcoma may appear cachectic or normal. In cutaneous angiosarcoma, physical examination findings may include:

Laboratory Findings

There are no specific laboratory findings associated with angiosarcoma.

Imaging Findings

  • The imaging modality of choice for angiosarcoma will depend on the location.
  • For pulmonary angiosarcoma, the imaging modality of choice is enhanced CT scan.[18] For other types angiosarcoma, the imaging modality of choice is MRI.

CT

On CT, findings of angiosarcoma may include:[18]

  • Vascular invasion
  • Nodular enhancement (common)
  • Hypoattenuating mass
  • Multicentric lesions
  • CT Pulmonary angiosarcoma Courtesy of Radiopedia

    CT Pulmonary angiosarcoma
    Courtesy of Radiopedia

MRI

On MRI, findings of angiosarcoma may include:

  • T1/T2: heterogeneous areas of hyperintensity suggestive of a mixed tumour and hemorrhage
  • T1 C+ (Gd): heterogeneous enhancement

Biopsy

Treatment

The mainstay of treatment for angiosarcoma is complete surgical resection with wide margins for local and locoregional disease in combination with preoperative or postoperative radiotherapy.[25][26] The role of adjuvant chemotherapy, is unclear. Adjuvant chemotherapy and/or radiotheray provide less mutilating surgery, and for patients with unresectable tumors or those who refuse surgery is an option.[27][28]

Medical Therapy

  • Since angiosarcomas are histologically anthracycline-sensitive, then initial systemic chemotherapy for unresectable and/or metastatic angiosarcomas include doxorubicin-based therapy with or without ifosfamide.[29]
  • However, taxane-based regimen may be preffered for initial therapy.Paclitaxel is effective for advanced angiosarcoma.[30]
  • Gemcitabine-based regimen is preferable to doxorubicin with or without ifosfamide for patients with significant clinical haert failure, due to heart-toxicity of doxorubicin.[31]
  • In addition, some vascular biologic molecules, with antiangiogenic characteristics including bevacizumab, sunitinib, and sorafenib, and with or without cytotoxic chemotherapy have shown dramatic responses in a small number of angiosarcoma patients.[32]

Surgery

  • Surgical resection in combination with radiation therapy is the treatment of choice for small angiosarcomas.[7]
  • Complete surgical resection with wide margins is preferred for local and locoregional angiosarcoma.[7] Owing to the tendency for local infiltration, surgical resection should be associated with preoperative or postoperative radiotherapy.[33]
  • Surgery is not recommended on patients with large sized angiosarcomas. The recurrence rate of angiosarcoma after surgery is 80%.It usually occures after a median of six months locally or distantly and the three-year disease-free and overall survival rates both are low.[34][35]

Prevention

Primary Prevention

There are no primary preventive measures available for angiosarcoma.

Secondary Prevention

Once diagnosed and successfully treated, patients with angiosarcoma are followed-up every 3, 6, or 12 months depending on the stage at diagnosis. Follow-up testing for angiosarcoma may include:[7]

References

  1. ↑ Barber W, Scriven P, Turner D, Hughes D, Wyld D (2010). "Epithelioid angiosarcoma: Use of angiographic embolisation and radiotherapy to control recurrent haemorrhage". J Surg Case Rep. 2010 (5): 7. doi:10.1093/jscr/2010.5.7. PMC 3649120. PMID 24946325.
  2. ↑ Matthew G. Fury, Cristina R. Antonescu, Kimberly J. Van Zee, Murray F. Brennan & Robert G. Maki (2005). "A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy". Cancer journal (Sudbury, Mass.). 11 (3): 241–247. PMID 16053668. Unknown parameter |month= ignored (help)
  3. ↑ M. Schlemmer, P. Reichardt, J. Verweij, J. T. Hartmann, I. Judson, A. Thyss, P. C. W. Hogendoorn, S. Marreaud, M. Van Glabbeke & J. Y. Blay (2008). "Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group". European journal of cancer (Oxford, England : 1990). 44 (16): 2433–2436. doi:10.1016/j.ejca.2008.07.037. PMID 18771914. Unknown parameter |month= ignored (help)
  4. ↑ Marie Karanian & Jean-Michel Coindre (2015). "[Fourth edition of WHO classification tumours of soft tissue]". Annales de pathologie. 35 (1): 71–85. doi:10.1016/j.annpat.2014.11.003. PMID 25532684. Unknown parameter |month= ignored (help)
  5. ↑ William M. Lydiatt, Snehal G. Patel, Brian O'Sullivan, Margaret S. Brandwein, John A. Ridge, Jocelyn C. Migliacci, Ashley M. Loomis & Jatin P. Shah (2017). "Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual". CA: a cancer journal for clinicians. 67 (2): 122–137. doi:10.3322/caac.21389. PMID 28128848. Unknown parameter |month= ignored (help)
  6. ↑ Muhammad Umar Jawad & Sean P. Scully (2010). "In brief: classifications in brief: enneking classification: benign and malignant tumors of the musculoskeletal system". Clinical orthopaedics and related research. 468 (7): 2000–2002. doi:10.1007/s11999-010-1315-7. PMID 20333492. Unknown parameter |month= ignored (help)
  7. ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ (2010). "Angiosarcoma". Lancet Oncol. 11 (10): 983–91. doi:10.1016/S1470-2045(10)70023-1. PMID 20537949.
  8. ↑ Y. Amo, M. Masuzawa, Y. Hamada & K. Katsuoka (2004). "Serum concentrations of vascular endothelial growth factor-D in angiosarcoma patients". The British journal of dermatology. 150 (1): 160–161. PMID 14746640. Unknown parameter |month= ignored (help)
  9. ↑ Johanna Manner, Bernhard Radlwimmer, Peter Hohenberger, Katharina Mossinger, Stefan Kuffer, Christian Sauer, Djeda Belharazem, Andreas Zettl, Jean-Michel Coindre, Christian Hallermann, Jorg Thomas Hartmann, Detlef Katenkamp, Kathrin Katenkamp, Patrick Schoffski, Raf Sciot, Agnieszka Wozniak, Peter Lichter, Alexander Marx & Philipp Strobel (2010). "MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema". The American journal of pathology. 176 (1): 34–39. doi:10.2353/ajpath.2010.090637. PMID 20008140. Unknown parameter |month= ignored (help)
  10. ↑ Tianhua Guo, Lei Zhang, Ning-En Chang, Samuel Singer, Robert G. Maki & Cristina R. Antonescu (2011). "Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions". Genes, chromosomes & cancer. 50 (1): 25–33. doi:10.1002/gcc.20827. PMID 20949568. Unknown parameter |month= ignored (help)
  11. ↑ Anthony P. Fernandez, Yang Sun, Raymond R. Tubbs, John R. Goldblum & Steven D. Billings (2012). "FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations". Journal of cutaneous pathology. 39 (2): 234–242. doi:10.1111/j.1600-0560.2011.01843.x. PMID 22121953. Unknown parameter |month= ignored (help)
  12. ↑ S. A. Sinclair, L. Sviland & S. Natarajan (1998). "Angiosarcoma arising in a chronically lymphoedematous leg". The British journal of dermatology. 138 (4): 692–694. PMID 9640382. Unknown parameter |month= ignored (help)
  13. ↑ R. J. W. de Keizer, D. de Wolff-Rouendaal & M. A. Nooy (2008). "Angiosarcoma of the eyelid and periorbital region. Experience in Leiden with iridium192 brachytherapy and low-dose doxorubicin chemotherapy". Orbit (Amsterdam, Netherlands). 27 (1): 5–12. doi:10.1080/01676830601168926. PMID 18307140.
  14. ↑ Rita Vora, Gopikrishnan Anjaneyan & Rajat Gupta (2014). "Cutaneous angiosarcoma of head and neck". Indian journal of dermatology. 59 (6): 632. doi:10.4103/0019-5154.143575. PMID 25484419. Unknown parameter |month= ignored (help)
  15. ↑ C. D. Fletcher, A. Beham, S. Bekir, A. M. Clarke & N. J. Marley (1991). "Epithelioid angiosarcoma of deep soft tissue: a distinctive tumor readily mistaken for an epithelial neoplasm". The American journal of surgical pathology. 15 (10): 915–924. PMID 1718176. Unknown parameter |month= ignored (help)
  16. ↑ Robin J. Young, Nicola J. Brown, Malcolm W. Reed, David Hughes & Penella J. Woll (2010). "Angiosarcoma". The Lancet. Oncology. 11 (10): 983–991. doi:10.1016/S1470-2045(10)70023-1. PMID 20537949. Unknown parameter |month= ignored (help)
  17. ↑ Andrea Ferrari, Iyad Sultan, Tseng Tien Huang, Carlos Rodriguez-Galindo, Ahmad Shehadeh, Cristina Meazza, Kirsten K. Ness, Michela Casanova & Sheri L. Spunt (2011). "Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database". Pediatric blood & cancer. 57 (6): 943–949. doi:10.1002/pbc.23252. PMID 21793180. Unknown parameter |month= ignored (help)
  18. ↑ 18.0 18.1 18.2 18.3 18.4 18.5 18.6 Sturgis EM, Potter BO. Sarcomas of the head and neck region. Curr Opin Oncol. 2003 May. 15(3):239-52
  19. ↑ Erich M. Sturgis & Bryan O. Potter (2003). "Sarcomas of the head and neck region". Current opinion in oncology. 15 (3): 239–252. PMID 12778019. Unknown parameter |month= ignored (help)
  20. ↑ Young, Robin J; Brown, Nicola J; Reed, Malcolm W; Hughes, David; Woll, Penella J (2010). "Angiosarcoma". The Lancet Oncology. 11 (10): 983–991. doi:10.1016/S1470-2045(10)70023-1. ISSN 1470-2045.
  21. ↑ Ayman H. Gaballah, Corey T. Jensen, Sarah Palmquist, Perry J. Pickhardt, Alper Duran, Gregory Broering & Khaled M. Elsayes (2017). "Angiosarcoma: clinical and imaging features from head to toe". The British journal of radiology. 90 (1075): 20170039. doi:10.1259/bjr.20170039. PMID 28471264. Unknown parameter |month= ignored (help)
  22. ↑ R. M. Donnell, P. P. Rosen, P. H. Lieberman, R. J. Kaufman, S. Kay, D. W. Jr Braun & D. W. Kinne (1981). "Angiosarcoma and other vascular tumors of the breast". The American journal of surgical pathology. 5 (7): 629–642. PMID 7199829. Unknown parameter |month= ignored (help)
  23. ↑ Ayman H. Gaballah, Corey T. Jensen, Sarah Palmquist, Perry J. Pickhardt, Alper Duran, Gregory Broering & Khaled M. Elsayes (2017). "Angiosarcoma: clinical and imaging features from head to toe". The British journal of radiology. 90 (1075): 20170039. doi:10.1259/bjr.20170039. PMID 28471264. Unknown parameter |month= ignored (help)
  24. ↑ Lifang Cui, Jixin Zhang, Xinmin Zhang, Hong Chang, Congling Qu, Jiangying Zhang & Dingrong Zhong (2015). "Angiosarcoma (Stewart-Treves syndrome) in postmastectomy patients: report of 10 cases and review of literature". International journal of clinical and experimental pathology. 8 (9): 11108–11115. PMID 26617830.
  25. ↑ W. M. Lydiatt, A. R. Shaha & J. P. Shah (1994). "Angiosarcoma of the head and neck". American journal of surgery. 168 (5): 451–454. PMID 7977971. Unknown parameter |month= ignored (help)
  26. ↑ Samia Arifi, Rhizlan Belbaraka, Rabie Rahhali & Nabil Ismaili (2015). "Treatment of Adult Soft Tissue Sarcomas: An Overview". Rare cancers and therapy. 3: 69–87. doi:10.1007/s40487-015-0011-x. PMID 27182479.
  27. ↑ Robin J. Young, Nicola J. Brown, Malcolm W. Reed, David Hughes & Penella J. Woll (2010). "Angiosarcoma". The Lancet. Oncology. 11 (10): 983–991. doi:10.1016/S1470-2045(10)70023-1. PMID 20537949. Unknown parameter |month= ignored (help)
  28. ↑ Guy Lahat, Asha R. Dhuka, Hen Hallevi, Lianchun Xiao, Changye Zou, Kerrington D. Smith, Thuy L. Phung, Raphael E. Pollock, Robert Benjamin, Kelly K. Hunt, Alexander J. Lazar & Dina Lev (2010). "Angiosarcoma: clinical and molecular insights". Annals of surgery. 251 (6): 1098–1106. doi:10.1097/SLA.0b013e3181dbb75a. PMID 20485141. Unknown parameter |month= ignored (help)
  29. ↑ N. Penel, A. Italiano, I. Ray-Coquard, L. Chaigneau, C. Delcambre, Y. M. Robin, B. Bui, F. Bertucci, N. Isambert, D. Cupissol, E. Bompas, J. O. Bay, F. Duffaud, C. Guillemet & J. Y. Blay (2012). "Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome". Annals of oncology : official journal of the European Society for Medical Oncology. 23 (2): 517–523. doi:10.1093/annonc/mdr138. PMID 21566149. Unknown parameter |month= ignored (help)
  30. ↑ Keith M. Skubitz & Philip A. Haddad (2005). "Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma". Cancer. 104 (2): 361–366. doi:10.1002/cncr.21140. PMID 15948172. Unknown parameter |month= ignored (help)
  31. ↑ Gino K. In, James S. Hu & William W. Tseng (2017). "Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations". Therapeutic advances in medical oncology. 9 (8): 533–550. doi:10.1177/1758834017712963. PMID 28794805. Unknown parameter |month= ignored (help)
  32. ↑ Kieuhoa T. Vo, Katherine K. Matthay & Steven G. DuBois (2016). "Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma". Clinical sarcoma research. 6: 9. doi:10.1186/s13569-016-0049-z. PMID 27274393.
  33. ↑ B. Ashleigh Guadagnolo, Gunar K. Zagars, Dejka Araujo, Vinod Ravi, Thomas D. Shellenberger & Erich M. Sturgis (2011). "Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp". Head & neck. 33 (5): 661–667. doi:10.1002/hed.21513. PMID 20960566. Unknown parameter |month= ignored (help)
  34. ↑ Darya Buehler, Stephanie R. Rice, John S. Moody, Patrick Rush, Gholam-Reza Hafez, Steven Attia, B. Jack Longley & Kevin R. Kozak (2014). "Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience". American journal of clinical oncology. 37 (5): 473–479. doi:10.1097/COC.0b013e31827e4e7b. PMID 23428947. Unknown parameter |month= ignored (help)
  35. ↑ Jojanneke M. Seinen, Emelie Styring, Vincent Verstappen, Fredrik Vult von Steyern, Anders Rydholm, Albert J. H. Suurmeijer & Harald J. Hoekstra (2012). "Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection". Annals of surgical oncology. 19 (8): 2700–2706. doi:10.1245/s10434-012-2310-x. PMID 22466664. Unknown parameter |month= ignored (help)

Template:WHTemplate:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Angiosarcoma&oldid=1550288"